India, May 6 -- Ernexa Therapeutics (ERNA) unveiled breakthrough preclinical results showing that its lead cell therapy candidate, ERNA-101 achieved complete tumor elimination and 100% long-term survival when combined with PD-1 blockade in syngeneic ovarian cancer models.
The company said the findings highlight the therapy's potential to overcome one of the biggest challenges in ovarian cancer- an immunologically "cold" tumor microenvironment.
Ovarian cancer, particularly high-grade serous ovarian carcinoma, remains a major unmet medical need, with most patients diagnosed at advanced stages and limited benefit from current immunotherapies due to strong tumor-driven immune suppression. Ernexa's new data suggest ERNA-101 may help unlock the...